Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 2Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Melanoma 17Neoplasm Metastasis 5Lymphoma, Non-Hodgkin 5Leukemia, Myeloid, Acute 5Hodgkin Disease 5Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neuroblastoma 4Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Carcinoma, Renal Cell 4Burkitt Lymphoma 4Uveal Melanoma 3Uterine Cervical Neoplasms 3Prostatic Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Hematologic Neoplasms 3Gliosarcoma 3Carcinoma, Merkel Cell 3Carcinoma, Basal Cell 3Vulvar Neoplasms 2Urogenital Neoplasms 2Urinary Bladder Neoplasms 2Urethral Neoplasms 2Thyroid Neoplasms 2Seminoma 2

Interventions

Magnetic Resonance Spectroscopy 9Specimen Handling 4Iodine-131 4Trastuzumab 3Thyrotropin Alfa 3Sorafenib 3Nivolumab 3Fluorodeoxyglucose F18 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3trametinib 2tipifarnib 2romidepsin 2omipalisib 2dabrafenib 2cabozantinib 2aldesleukin 2Triiodothyronine 2Sunitinib 2Ipilimumab 2Iodine-124 2CTLA-4 Antigen 2Bortezomib 2Biopsy 2vandetanib 1ulixertinib 1trastuzumab biosimilar HLX02 1tanespimycin 1sargramostim 1sapanisertib 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Thyroid Neoplasms × Ipilimumab × Clear all
NCT02834013 2026-06-03

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
798 enrolled
CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT03914300 2026-06-01

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
11 enrolled 11 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡